Side effects-direct-acting antivirals
Related On This Website - Side Effects: Peginterferon and Ribavirin
HCV Drug Interaction Charts
Updates
2013/HCV Triple-therapy Side Effects
Archives
Dec 2012
Dec 28
HCV Drug Incivek (telaprevir) - View Rash Grade 1 and 2
Dec 26
Lack of a Clinically Significant Drug-Drug Interaction in Healthy Volunteers Between
the Hepatitis C Virus Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir
FDA Drug Safety Podcast: Serious skin reactions after combination
treatment with the Hepatitis C drugs Incivek (telaprevir), peginterferon alfa, and ribavirin
Dec 15
FDA Drug Safety Communication/Data Summary: Serious skin reactions after combination
treatment with the Hepatitis C drugs Incivek (telaprevir), peginterferon alfa, and ribavirin
INCIVEK® (telaprevir)-Updates label after reports of a ‘small
number of fatal skin reactions’
Ribavirin dose reduction, erythropoietin combat HCV
anemia
Dec 13
Anemia Management During PI-based HCV Therapy: Ribavirin Dose
Reduction is the Right Course of Action
Dec 11
Triple therapy has poor safety in cirrhotic hepatitis C
The Liver Meeting: 63nd Annual Meeting of the
American Association for the Study of Liver Diseases
PDF - drug interaction studies
*including Investigational drugs
Nov 2012
Nov 18
Hepatitis C-Managing Adverse Effects and Complications in Completing Treatment
Hepatitis C Treatment’s Side Effects Can Now Be Studied in the Lab
Secondary bronchiolitis obliterans organizing pneumonia during treatment of
chronic hepatitis C: role of pegylated interferon alfa-2a.
Nov 2
FDA Hepatitis Update - Victrelis (boceprevir) labeling update
Candidiasis and other oral mucosal lesions during and after interferon therapy for HCV-related chronic liver diseases
Oral lichen planus (OLP) is seen frequently in patients with hepatitis C virus
(HCV) infection. The aim of this study was to evaluate the occurrence of oral
candidiasis, other mucosal lesions, and xerostomia (dry mouth) during interferon (IFN)
therapy for HCV infection.
Sept 2012
Oct 20
Autoimmune thyroiditis in patients with chronic hepatitis C
virus during IFN-alpha therapy
Sept 27
An Exploration of Depressive Symptoms in Hepatitis C Patients Taking
Interferon-alpha: Increase in Sickness Behaviors but not Negative Cognitions
Sept 26
Coeliac disease and C virus-related chronic hepatitis: a non association
PEG interferon-alpha treatment was not associated with development of coeliac disease either clinical or serological.
Sept 20
Fatigue before, during and after antiviral therapy of chronic hepatitis C: Results from the Virahep-C study
Withdrawing interferon-α from psychiatric patients: clinical care or unjustifiable stigma?
Sept 16
Retinopathy associated with interferon therapy in patients with hepatitis C virus
Sept 14
Is Combination Therapy for Chronic Hepatitis C Toxic for Cardiac Function?
Association of interferon-alpha and ribavirin-induced thyroiddysfunction with severity
of disease and response to treatment in pakistani asian patients of chronic hepatitis C.
Sept 1
HEALTHWISE: Hepatitis C Treatment Tips from Patients
Acute inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alfa-2a in a patient with chronic hepatitis C virus infection: a case report
Aug 2012
Aug 29
Ischemic colitis during interferon-ribavirin therapy for chronic hepatitis C: A case report
Aug 15
Safety of Telaprevir for Chronic Hepatitis C Virus Infection: A Meta-Analysis of Randomized Controlled Trials
Drug Interactions - Peginterferon and Cytochrome P450
Aug 8
Article Of Interest - Preventive Nutritional Support Helpful During Hepatitis C Therapy
CME- Understanding Drug-Drug Interactions in This New Triple-Therapy Era
Hypertension ups retinopathy risk with HCV treatment
Aug 1
Telaprevir, Incivek & sex
Interferon, hep c and sex: Men's issues
FDA Hepatitis Update - Victrelis (boceprevir) label updated for drug-drug interactions
Curing Fatigue with Treatment
July 2012
July 17
Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus
July 10
PEG-IFN treatment in hypertensive patients with HCV may cause retinopathy
Patients with chronic hepatitis C, particularly those with hypertension, were prone to developing retinopathy during treatment with pegylated interferon alpha and ribavirin in a recent study.
Neuropsychiatric Symptoms-Brain Fog and HCV
June 2012
June 28
FDA Hepatitis Update - Incivek (telaprevir) product labeling revised
Drug Interactions - Telaprevir and buprenorphine.
Drug Interactions - Boceprevir and ciclosporin or tacrolimus.
June 17
Depression Induced by Interferon Therapy
Quality of Life Undiminished by Telaprevir in Chronic Hepatitis C
Although the addition of telaprevir to peginterferon/ribavirin therapy for treatment of chronic hepatitis C exacerbates treatment-related side effects, the triple combination does not diminish patient quality of life relative to treatment with the peginterferon/ribavirin regimen alone, a study has shown.
Annals Of Hepatology July-August, Vol. 11 No. 4, 2012
Ann Hepatol 2012; 11 (4) LETTERS TO EDITOR
Pegylated interferon, but not conventional interferon therapy induced severe skin lesions
Zhengxiao Li, Fanpu Ji, Yan Zheng, Jingang An, Zhenhui Peng
MAY 2012
Incivek Rash Reports: What HIV/Hepatitis C-Coinfected People
Need to Know
Rashes have been seen for many years now in hepatitis C (HCV) therapy, ever since we started widely using ribavirin after finding that it increased HCV cure rates. Ribavirin can cause speckled rash all over the body. (Peg-interferon can
cause rash too, but it is usually just seen at the injection sites.) It turns out that Incivek (telaprevir), one of the HCV protease
inhibitors approved last year, is also associated with rash. When Incivek was presented at the U.S. Food and Drug Administration meetings for drug approval,this rash problem was discussed in great detail....
Identification and Management of Adverse Events
Anticipating the adverse effects of telaprevir and boceprevir, informing patients about their risk, and being prepared to manage them is important for safe and successful outcomes from triple therapy.
New Antivirals Show Poor Safety in Hepatitis C With Cirrhosis
Interferon - Hepatitis C Drug Can Cause Depression
Digital Liver Disease Journal
The "Digital Liver Disease Journal" is an official digital educational resource from the American Association for the Study of Liver Diseases.
Management of adverse events during the treatment of chronic hepatitis C infection (pages 54–57)
Abstract
Watch the interview with the authors
Watch the video presentation of this article
Case Study - Onset of Type 1 Diabetes Mellitus During Pegylated-interferon Alfa and Ribavirin Therapy for Chronic Hepatitis C Virus Infection
Download PDF (129 KB)
April 2012
Interferon-Associated Retinopathy and Non-HCV Related Eye Conditions
Updated information on drug interactions between Victrelis boceprevir) and certain boosted HIV protease inhibitor
drugs
Telaprevir May Cause Severe Cutaneous Eruptions NEW YORK (Reuters Health)
Hepatitis C drug alisporivir is effective, but pancreatitis a concern EASL-Alisporivir: Pancreatitis Forces Halt to HCV Drug
Trial
Summary Of The 47th European Association for the Study of the Liver EASL
EASL: Telaprevir and Boceprevir Effective but Cause Serious Side Effects in Patients With Cirrhosis
EASL-Telaprevir and boceprevir show high rate of serious side-effects in hepatitis C patients with urgent need of
treatment
A real-world study of new hepatitis C protease inhibitors in the group of patients who have been told they should
not wait for newer, experimental antivirals has shown a much higher rate of serious adverse events and treatment
discontinuations than in clinical trials, Dr Christophe Hézode reported on behalf of the French Compassionate Use of Protease Inhibitors in Cirrhotics cohort study at the 2012 International Liver Congress in Barcelona on Thursday.
More News on Drug Interactions With New HCV Drugs -- This Time With Daclatasvir
Mar 2012
Australia: Side-effect fears stall hepatitis C drugs
March Journal Of Hepatology - Articles In Press
Severe Cutaneous Eruptions on Telaprevir
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
To the editor:
Since its approval by the Food and Drug Administration in May 2011, telaprevir, a novel serine protease inhibitor, in combination with peginterferon and ribavirin has been increasingly used as an effective treatment for hepatitis C virus (HCV)[1]. In Phase II and III clinical trials involving over 3,800 patients, a cutaneous eruption, usually eczematous,
occurred in 56% of patients compared to 34% taking peginterferon and ribavirin alone[2]. Furthermore, 3.7% of telaprevir-treated patients developed severe cutaneous adverse events. These events included 11 patients considered to have
drug reaction with eosinophilia and systemic symptoms (DRESS), but of these, only one was definite, two were probable, and the remainder were possible, according to diagnostic criteria proposed by Kardaun et al[2,3]. Herein we report three patients out of 56 patients at risk (5%) taking telaprevir, peginterferon, and ribavirin at our institution who developed probable and definite DRESS.
Download PDF Here
Related-Incivek-Help Recognizing Rash Severity:Photos and grading system
View List-FDA Alert-Statins and HIV or Hepatitis C Drugs
Protease inhibitors and statins taken together may raise the blood levels of statins and increase the risk of myopathy, kidney damage, and kidney failure, which can be fatal.View the list of HIV or HCV Drugs
which interact with statins Here Or Here
Protease inhibitors: Silver bullets for chronic hepatitis C infection?
Recent trials evaluated the safety and efficacy of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek),
added tostandard care with pegylated interferon and ribavirin, in patients with chronic hepatitis C virus (HCV) infection. These drugs open the door for triple therapy and other new therapies involving combinations of other direct-acting antiviral
agents to become the new standard of care for this population.
This review summarizes the results of recent phase 3 clinical trials that evaluated the safety and efficacy of these new agents
*see table 2 below - Adverse events reported in clinical trials of boceprevir and telaprevir
Click here to continue on to study.
Feb 2012
Boceprevir and telaprevir for hepatitis C: safety management in
clinical practice
Merck does not recommend the coadministration of VICTRELIS and
ritonavir-boosted HIV protease inhibitors.
Letter from Merck to physicians:
VICTRELIS is not indicated for use in patients who are
infected with both HIV-1 and chronic HCV. The safety and efficacy of VICTRELIS™
(boceprevir) has not been established in this coinfected population. Merck does
not recommend the coadministration of VICTRELIS and ritonavir-boosted HIV
protease inhibitors
Hepatitis News Ticker: Anemia During
HCV Therapy - INCIVEK and VICTRELIS
FDA-Safety
Alert
Victrelis (boceprevir) and Ritonavir-Boosted HIV Protease
Inhibitor Drugs - Drug Interactions
Drug
Interaction Charts
Telaprevir/Boceprevir/Peg-IFN alfa
Direct-Acting Antiviral (DAA) Therapy
Offered at -"Projects In Knowledge" are six chapters on what you
need to know about "Direct-Acting Antiviral (DAA) Therapy" for hepatitis C.
The site is a great source for easy to understand information, although
like any site offering continuing medical education - CME, it requires a
free quick registration.
The six chapters can be a useful learning tool for
anyone considering hepatitis C therapy. The last chapter
"Neuropsychiatric Adverse Effects" has been made available on the blog.
Once you register at "Projects In Knowledge"
view all eHandbook Chapters -- here.
Drug Interaction News & Archive
The therapeutic area of hepatitis, and in particular hepatitis
drug interactions, is a rapidly changing field. We endeavour to keep abreast of
the latest developments in the area and offer up-to-date details on hot topics
of interest and recent publications.
Video-Three minutes into the presentation you will be prompted to register
Managing HCV Medication Side Effects
Mark Sulkowski, MD Professor of Medicine,
Johns Hopkins University School of Medicine, Medical Director, Viral Hepatitis Center
Strategies for Success: Management of Telaprevir-Associated Rash
and Anorectal Symptoms
Managing Side Effects of New Hepatitis C Protease Inhibitors
Dermatological side effects of hepatitis C and its treatment:
Patient management in the era of direct-acting antivirals
Telaprevir-Am I Anal Or Do I Itch?
Hepatitis C - Dry Mouth andTreatment
2011
Interferon-Induced Mania
Dec 2011
Irreversible Anterior Ischemic Optic Neuropathy Complicating
Interferon Alpha and Ribavirin Therapy
Retinopathy associated with pegylated interferon and ribavirin
in patients with hepatitis C
Hepatitis C- Rare case of pegylated IFN-α induced destructive
thyroiditis followed by Graves' disease
Fever-Oral Temperature Changes After Initial Peginterferon
Alfa-2a Injection in Chronic Hepatitis C Patients Reflect Host-Inteferon
Responsiveness
Depressive symptoms influence treatment course among Hep C
patients
Nov 2011
Hepatitis C -The Brain on Fire: Inflammation and Depression
Psychiatric Complications of Hepatitis C Therapy: Part 1 and 2
Oct 2011
Video-Side Effects Of Hepatitis C Treatment Oct 2011
Sept 2011
Dermatological side effects-Patient management in the era of
direct-acting antivirals
Use of New HCV Protease Inhibitors ‘Not That Simple’
FDA Transcripts Telaprevir/Boceprevir April Advisory Committee
Meeting
Includes Side Effects
Telaprevir/Incivek Prescribing Information
Medication Guide
VICTRELIS™- Boceprevir: Prescribing Information and Medication
Guide
Video-What Is Hepatitis C? HCV Therapy W-pegylated interferon
and ribavirin
Hepatitis C Therapy Can Cause Mild Depression to Spike
Aug 2011
Retinopathy associated with pegylated interferon and ribavirin
in patients with hepatitis C
July 2011
Hepatitis C Drug Incivek (telaprevir); What are the side effects ?
April 2011
Adverse Effects: Management of Hepatitis C Antiviral Therapy
Hepatitis C Therapy; Adherence to Treatment and Quality of Life
Depression May Complicate Hepatitis C Therapy
March-Jan 2011
Serous Retinal Detachments Complicating Interferon-α and
Ribavirin Treatment in Patients with Hepatitis C
Adverse Effects: Management of Hepatitis C Antiviral Therapy
Acute pericarditis due to pegylated interferon alpha therapy for
chronic HCV hepatitis - Case report
Hepatitis C Thyroid and Treatment/Pegylated interferon
2010
Hepatitis C: White Blood Count During Therapy
Hair Loss During Hepatitis C Therapy
Hepatitis C: Anemia And Other Side Effects During Treatment
Risk factors for infection during treatment for chronic Hep C
Skin Rash During HCV Therapy/Pictures Chronic cough/Pegylated interferon/ribavirin In HCV
Therapy
HCV Treatment and Neutropenia(low white count)